Gilead to Acquire PepStar’s HCXT-2001 IL-23R Inhibitor Program
Gilead Sciences entered a definitive agreement to acquire PepStar Therapeutics’ oral IL-23R inhibitor program, including lead asset HCXT-2001.
Story updates
08:11:12 PM UTC
SquawkNews
Gilead Sciences NASDAQ:GILD said on Thursday it will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental bowel disease treatment, for $1.275 billion in cash.
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.Key Highlights“HCXT-2001 adds a…